Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Postnatal depression which persists beyond six months after birth and is severe, increases the risk of children exhibiting behavioural problems, achieving lower GCSE mathematics grades at 16 years and having depression at 18 years of age.

Image courtesy of Shutterstock

Postnatal depression which is persistent (whether moderate or severe) increases mothers’ risk of continuing to experience depressive symptoms beyond the postnatal year, with high levels found up until 11 years after childbirth.

Available research suggests that postnatal depression is associated with increased risks to children’s development affecting a range of domains. The effects are variable with some evidence suggesting that brief episodes, while distressing to the mother, may not impact negatively on children’s development. However, episodes of depression which persist for six months or more in duration may increase the risk for children. Identifying women at most risk is important both for women’s mental health and children’s development. The authors investigated whether depression has a similar impact when it is, or is not, persistent at either moderate or severe levels. Researchers from the Universities of Oxford, Bristol, Reading and UCLA in a new paper in JAMA Psychiatry tracked changes in mothers’ depressive symptoms following the postnatal year and differences in children’s development when postnatal depression was, or was not, persistent.

Find out more (University of Oxford website)

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.

Oxford-led technology to help those at high risk from Covid-19

Coronavirus COVID-19 General Research

More people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.